Phase 3 Eczema Trial, Recruiting NCT06880276 Sponsor: Qilu Pharmaceutical Co., Ltd. Condition: Eczema
Back to Eczema

Phase 3 Eczema Trial, Recruiting

NCT06880276
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (male or female)
  • You have been diagnosed with atopic dermatitis (a type of eczema) using a specific medical standard, and you have had eczema/atopic dermatitis for at least 1 year before joining the study
  • At the time of screening and the start of the trial, your condition is rated as "2" or "3" on a standard severity scale (meaning mild to moderate symptoms)
  • Your atopic dermatitis affects the head and neck (not including the scalp), trunk (chest/back/stomach), and/or limbs (arms and legs), covering between 3% and 20% of your total body surface area

Who may not be able to join:

  • You have other health conditions or circumstances that the study doctor believes could interfere with how the study results are measured
  • Your atopic dermatitis is considered unstable by the study doctor — meaning it is either getting much better on its own or getting much worse very quickly
  • You have received a biologic medication (such as Dupilumab) for atopic dermatitis within the past 3 months before the study starts, or within a certain timeframe based on how long the drug stays in your body (whichever is longer)
  • You have taken certain oral or topical JAK inhibitor medications (such as Tofacitinib, Upadacitinib, Baricitinib, Abrocitinib, or similar drugs) within 4 weeks before the study starts, or within a certain timeframe based on how long the drug stays in your body (whichever is longer)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Xinghua Gao, Doctor, First Hospital of China Medical University

Phone: 13256161060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Qilu Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
16 May 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 8

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov